Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection

Antiviral Research

Volumn 114, Issue , 2015, Pages 106-112

  Ahmed, Muhammad S ^a   Jacques, Laura C ^a   Mahallawi, Waleed ^a   Ferrara, Francesca ^b   Temperton, Nigel ^b   Upile, Nav ^c   Vaughan, Casey ^c   Sharma, Ravi ^c   Beer, Helen ^d   Hoschler, Katja ^e   McNamara, Paul S ^a   Zhang, Qibo ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Anti hemagglutinin antibody; Cross reactive immunity; Influenza virus; Pandemic H1N1 infection; Serum antibody; Virus neutralization

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MAJOR CLINICAL STUDY; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; BLOOD; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMIC; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; YOUNG ADULT;

EID: 84920000923     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.12.008     Document Type: Article

References (24)

1. Ahmed, M.S., Derbyshire, S., Flanagan, B., Loh, C., McCormick, M., Barocchi, M., et al., 2014. Immune responses to pneumococcal pilus RrgA and RrgB antigens and their relationship with pneumococcal carriage in humans. J. Infect. 68 (6), 562-571.
2. Air, G., 1981. Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. Proc. Natl. Acad. Sci. U.S.A. 78, 7639-7643.
3. Baguelin, M.H., Hoschler, K., Stanford, E., Waight, P., Hardelid, P., Andrews, N., Miller, E., 2011. Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS One 6 (2), e17074.
4. Bosman, A., Meijer, A., Koopmans, M., 2005. Final analysis of Netherlands avian influenza outbreaks reveals much higher levels of transmission to humans than previously thought. Euro Surveill. 10 (12), 2616.
5. Corti, D., Jr. S, A., Pinna, D., Silacci, C., Fernandez-Rodriguez, B., Vanzetta, F., 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. [Research Support, Non-U.S. Gov't] 120 (5), 1663-1673. http://dx.doi.org/10.172/JCI41902 (Epub 2010 Apr 12).
6. Corti, D., Voss, J., Gamblin, S.J., Codoni, G., Macagno, A., Jarrossay, D., et al., 2011. A neutralizing antibody selected fromplasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333 (6044), 850-856 (2011 August 12).
7. Ferrara, F., Molesti, E., Böttcher-Friebertshäuser, E., Cattoli, G., Corti, D., Scott, S.D., et al., 2013. The human transmembrane protease serine 2 is necessary for the production of group 2 influenza A virus pseudotypes. J. Mol. Genet. Med. 7, 309-314.
8. Hai, R., Krammer, F., Tan, G.S., Pica, N., Eggink, D., Maamary, J., et al., 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86 (10), 5774-5781 (2012 May 15).
9. Kaur, K, Sullivan, M, Wilson, PC, 2011. Targeting B cell responses in universal influenza vaccine design.. Trends Immunol. 32 (11), 524-531.
10. Krause, J.C., Tumpey, T.M., Huffman, C.J., McGraw, P.A., Pearce, M.B., Tsibane, T., 2010. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J. Virol. 84 (6), 3127-3130 (2010 March 15).
11. Li, G.-M., Chiu, C., Wrammert, J., McCausland, M., Andrews, S.F., Zheng, N.-Y., et al., 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. U.S.A. 109 (23), 9047-9052.
12. Mahallawi, W.H., Kasbekar, A.V., McCormick, M.S., Hoschler, K., Temperton, N., Leong, S.C., et al., 2013. Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses. J. Virol. 87 (10), 5331-5339 (2013 May 15).
13. Miller, E., Hoschler, K., Hardelid, P., Stanford, E., Andrews, N., Zambon, M., 2010. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375 (9720), 1100-1108.
14. Miura, K., Orcutt, A.C., Muratova, O.V., Miller, L.H., Saul, A., Long, C.A., 2008. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26 (2), 193-200.
15. Molesti, E., Cattoli, G., Ferrara, F., Böttcher-Friebertshäuser, E., Terregino, C., Temperton, N., 2013. The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses. J. Mol. Genet. Med. 7, 315-320.
16. Palese, P, Wang, TT, 2011. Why do influenza virus subtypes die out? A hypothesis. mBio 2 (5), 5. http://dx.doi.org/10.1128/mBio.00150-11 (2011 September/October).
17. Pica, N., Hai, R., Krammer, F, Wang, T.T., Maamary, J., Eggink, D., 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci.. http://dx.doi.org/10.1073/pnas1200039109, 2012 January 30.
18. Schneider, J., Gilbert, S.C., Hannan, C.M., Dégano, P., Prieur, E., Sheu, E.G., et al., 1999. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170, 29-38.
19. Smith G.E., et al., 1998. Method for Producing Influenza Hemagglutinin Multivalent Vaccines Using Baculovirus. MG-PMC, LLC, assignee. U.S. Patent 5,762,939 (09 Jun. 1998).
20. Stevens, J., Corper, A.L., Basler, C.F., Taubenberger, J.K., Palese, P., Wilson, I.A., 2004. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303 (5665), 1866-1870 (2004 March 19).
21. Temperton, N.J., Hoschler, K., Major, D., Nicolson, C., Manvell, R., Hien, V.M., et al., 2007. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir. Viruses 1 (3), 105-112.
22. Tong, S., Li, Y., Rivailler, P., Conrardy, C., Castillo, D.A.A., Chen, L.-M., et al., 2012. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. U.S.A. 109 (11), 4269-4274 (2012 February 27).
23. Wrammert, J., Koutsonanos, D., Li, G.M., Edupuganti, S., Sui, J., Morrissey, M., et al., 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208 (1), 181-193.
24. Xu, R., Ekiert, D.C., Krause, J.C., Hai, R., Crowe, J.E., Wilson, I.A., 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328 (5976), 357-360 (2010 April 16).